Effects of Escalating Temporary Mechanical Circulatory Support in Patients With Worsening Cardiogenic Shock.


Journal

Texas Heart Institute journal
ISSN: 1526-6702
Titre abrégé: Tex Heart Inst J
Pays: United States
ID NLM: 8214622

Informations de publication

Date de publication:
01 11 2022
Historique:
entrez: 20 12 2022
pubmed: 21 12 2022
medline: 23 12 2022
Statut: ppublish

Résumé

Cardiogenic shock-related mortality is substantial, and temporary mechanical circulatory support (MCS) devices are frequently used. The authors aimed to describe patient characteristics and outcomes in patients with worsening cardiogenic shock requiring escalation of temporary MCS devices. Worsening cardiogenic shock was defined as persistent hypotension, increasing doses of vasopressors/inotropes, worsening hypoperfusion, or worsening invasive hemo-dynamics. Escalation of temporary MCS devices was defined as adding or exchanging an existing MCS device. Variables were evaluated by logistic regression models and receiver operating characteristic curves. From July 1, 2016, to July 1, 2018, a total of 81 consecutive patients experienced worsening cardiogenic shock requiring temporary MCS escalation. The etiology of cardiogenic shock was heterogeneous (33.3% acute myocardial infarction and 61.7% decompen-sated heart failure). Younger age (<62 years), lower body mass index (<28.7 kg/m2), lower preescalation lactate levels (<3.1 mmol/L), higher postescalation blood pressure (>85 mm Hg), and lower postescalation lactate levels (<2.9 mmol/L) were associated with greater odds of survival. The presence of a pulmonary artery catheter at the time of escalation was associated with greater odds of survival (P = .05). Escalation of temporary MCS in Society for Cardiovascular Angiography and Interventions stage E shock was associated with 100% mortality (P = .05). The rate of overall survival to discharge was 32%. Patients requiring temporary MCS escalation represent a high-risk cohort. Further work is needed to improve outcomes in this patient population.

Sections du résumé

BACKGROUND
Cardiogenic shock-related mortality is substantial, and temporary mechanical circulatory support (MCS) devices are frequently used. The authors aimed to describe patient characteristics and outcomes in patients with worsening cardiogenic shock requiring escalation of temporary MCS devices.
METHODS
Worsening cardiogenic shock was defined as persistent hypotension, increasing doses of vasopressors/inotropes, worsening hypoperfusion, or worsening invasive hemo-dynamics. Escalation of temporary MCS devices was defined as adding or exchanging an existing MCS device. Variables were evaluated by logistic regression models and receiver operating characteristic curves.
RESULTS
From July 1, 2016, to July 1, 2018, a total of 81 consecutive patients experienced worsening cardiogenic shock requiring temporary MCS escalation. The etiology of cardiogenic shock was heterogeneous (33.3% acute myocardial infarction and 61.7% decompen-sated heart failure). Younger age (<62 years), lower body mass index (<28.7 kg/m2), lower preescalation lactate levels (<3.1 mmol/L), higher postescalation blood pressure (>85 mm Hg), and lower postescalation lactate levels (<2.9 mmol/L) were associated with greater odds of survival. The presence of a pulmonary artery catheter at the time of escalation was associated with greater odds of survival (P = .05). Escalation of temporary MCS in Society for Cardiovascular Angiography and Interventions stage E shock was associated with 100% mortality (P = .05). The rate of overall survival to discharge was 32%.
CONCLUSION
Patients requiring temporary MCS escalation represent a high-risk cohort. Further work is needed to improve outcomes in this patient population.

Identifiants

pubmed: 36538600
pii: 489428
doi: 10.14503/THIJ-21-7615
pmc: PMC9809073
pii:
doi:

Substances chimiques

Lactates 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2022 by the Texas Heart® Institute, Houston.

Références

Catheter Cardiovasc Interv. 2012 Oct 1;80(4):593-600
pubmed: 21954053
N Engl J Med. 2017 Dec 21;377(25):2419-2432
pubmed: 29083953
J Am Coll Cardiol. 2014 Oct 7;64(14):1407-15
pubmed: 25277608
Am J Cardiol. 2017 Mar 15;119(6):845-851
pubmed: 28040188
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):29-37
pubmed: 31104355
N Engl J Med. 1999 Aug 26;341(9):625-34
pubmed: 10460813
Arch Intern Med. 2005 Jul 25;165(14):1643-50
pubmed: 16043684
Eur J Heart Fail. 2019 Nov;21(11):1370-1378
pubmed: 31339222
Circulation. 2017 Oct 17;136(16):e232-e268
pubmed: 28923988
J Heart Lung Transplant. 2013 Jan;32(1):106-11
pubmed: 23260710
J Am Coll Cardiol. 2019 Apr 16;73(14):1781-1791
pubmed: 30975295
Circulation. 2020 Apr 7;141(14):1184-1197
pubmed: 32250695
Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1173-1183
pubmed: 31025538
Clin Res Cardiol. 2015 Jul;104(7):566-73
pubmed: 25637294
Eur Heart J. 2015 May 21;36(20):1223-30
pubmed: 25732762
J Card Fail. 2019 May;25(5):364-371
pubmed: 30858119
Artif Organs. 2014 Nov;38(11):940-4
pubmed: 24788069
Circ Heart Fail. 2020 Mar;13(3):e005853
pubmed: 32164431
Ann Thorac Surg. 2014 Feb;97(2):610-6
pubmed: 24210621
N Engl J Med. 2012 Oct 4;367(14):1287-96
pubmed: 22920912
J Am Coll Cardiol. 2004 Jul 21;44(2):340-8
pubmed: 15261929
J Am Coll Cardiol. 2019 Oct 29;74(17):2117-2128
pubmed: 31548097
J Am Heart Assoc. 2014 Jan 13;3(1):e000590
pubmed: 24419737
Eur Heart J. 2013 Jan;34(2):112-20
pubmed: 22513777
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E213-E219
pubmed: 31925996

Auteurs

Iyad N Isseh (IN)

Inova Heart and Vascular Institute, Falls Church, Virginia.

Sarah Gorgis (S)

Division of Cardiology, Henry Ford Hospital, Detroit, Michigan.

Carina Dagher (C)

Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan.

Shivani Sharma (S)

Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan.

Mir B Basir (MB)

Division of Cardiology, Henry Ford Hospital, Detroit, Michigan.

Sachin Parikh (S)

Division of Cardiology, Henry Ford Hospital, Detroit, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH